-
Fosinopril Sodium: From Endpoints to Assays
2026-09-10
Fosinopril sodium offers a precise framework for hypertension research, but its value depends on connecting ACE target engagement with hemodynamic, renal, and cardiac endpoints. This article translates lessons from the VERTIS CV outcomes trial into a practical, evidence-aware assay strategy.
-
A-1210477: MCL-1 Inhibitor Workflow
2026-09-10
A-1210477 enables selective interrogation of MCL-1-dependent survival, mitochondrial apoptosis, and combination responses in cancer models. This practical guide connects compound handling with mechanism-focused assays, controls, and troubleshooting for reproducible cancer research.
-
NAT1–ENO1–Lactate Signaling in Colorectal Cancer
2026-09-09
A 2026 MedComm study identifies NAT1 as a metabolic–immune regulator in colorectal cancer, linking ENO1 acetylation and lactate production to TRAF6-dependent PD-L1 stabilization. Its combination of database analysis, multi-omics, patient data, and mouse models provides a mechanistic framework for understanding how tumor glycolysis can influence checkpoint blockade response.
-
α-Linolenic Acid: Designing Causal Lipid Assays
2026-09-09
Explore how α-Linolenic Acid and ALA can be studied as metabolic substrates, membrane inputs, and signaling modifiers. This evidence-aware guide uses a recent arachidonic acid immunology study to develop more rigorous assay logic without conflating ALA with arachidonic acid.
-
How Impending Cell Death Can Seed Metastasis
2026-09-08
Conod, Silvano, and Ruiz i Altaba show that tumor cells surviving an impending-death experience can acquire stable prometastatic states called PAMEs. The study links these states to ER stress, PERK-CHOP signaling, GLI and NANOG-dependent reprogramming, and a cytokine-mediated interaction with neighboring PIM cells, providing a mechanistic framework for how treatment-associated stress may promote dissemination.
-
Phenothiazines, ROS, and Macrophage Antibacterial Defense
2026-09-08
Qiu and colleagues show that phenothiazines strengthen macrophage control of intracellular bacteria through coordinated reactive oxygen species accumulation, lysosomal activation, and autophagy. The study supports a host-directed antibacterial strategy, while its class-level design means that compound-specific effects, including those of promethazine hydrochloride, require separate validation.
-
Oral Colon Cancer Nanotherapy with Dextran Microgels
2026-09-07
The reference study developed an orally administered, colon-responsive system in which dextran microgels protect cisplatin/SPION lipid nanoparticles during gastrointestinal transit and release them in the colon. Its combination of dextran- and folic-acid-mediated targeting with chemotherapy and magnetic hyperthermia produced strong antitumor activity in an orthotopic mouse model while illustrating the formulation challenges that must be addressed before clinical translation.
-
Intravesical p21 mRNA-LNP Therapy for Bladder Cancer
2026-09-07
Zeng and colleagues developed chemically modified p21 mRNA-loaded lipid nanoparticles for localized intravesical treatment of bladder cancer. Their preclinical evidence links restored nuclear p21 expression with cell-cycle suppression, DNA-damage signaling, apoptosis, tumor growth inhibition, and preservation of bladder architecture, while also highlighting delivery and translational constraints.
-
Regorafenib Workflows for Cancer Biology
2026-09-05
Build reproducible angiogenesis, migration, pathway, and tumor xenograft experiments with Regorafenib (BAY 73-4506). This practical guide connects multikinase inhibition with the newer RRM2–ERK/E2F3 melanoma findings and provides assay-specific optimization strategies.
-
TUNEL Apoptosis Detection Kit: Renal Research Guide
2026-09-04
Use the TUNEL Apoptosis Detection Kit (DAB) to localize apoptotic DNA fragmentation in renal amyloidosis models, tissue sections, and cultured cells with a standard light microscope. This practical guide connects rosemary-extract research with assay setup, controls, quantification, and troubleshooting for reproducible programmed cell death research.
-
PRINT: RNA-Mediated Safe-Harbor Transgene Insertion
2026-09-04
The reference study introduces PRINT, an RNA-only strategy that uses avian R2 retroelement proteins to insert transgenes at a multicopy human safe-harbor locus through target-primed reverse transcription. Its results show that direct cDNA synthesis can support efficient, site-directed transgene insertion while avoiding a donor-DNA intermediate, although locus scope, cargo size, cell-type portability, and long-term genomic behavior remain important open questions.
-
LNP Surface Charge and V-ATPase Drive Tropism
2026-09-03
The reference study proposes that lipid nanoparticle tropism is governed by a synergy between LNP surface charge and the V-ATPase activity of recipient cells. Its in vitro and in vivo experiments connect cellular endo/lysosomal state with delivery performance, offering a mechanistic framework for interpreting liver- versus lung-biased nucleic acid delivery.
-
Laser-Particle Barcoding for Scalable Single-Cell Tracking
2026-09-03
The reference study introduces combinatorial laser-particle barcodes that can distinguish and track millions of live cells using optically readable spectral signatures. Its theoretical error framework, improved tagging strategy, and biocompatibility analysis provide a practical foundation for linking repeated imaging with flow, sequencing, and other single-cell measurements.
-
MCL-1 Inhibition: From Mechanism to Translation
2026-09-02
A mechanistic and translational framework for using A-1210477 to interrogate MCL-1 dependence, mitochondrial apoptosis, combination sensitivity, and the limits of moving an in vitro research tool toward therapeutic hypotheses.
-
GSK 2837808A: LDHA Inhibition Workflow
2026-09-02
GSK 2837808A is a potent lactate dehydrogenase A inhibitor for connecting LDHA activity with lactate output, glucose consumption, and tumor-cell signaling. This practical workflow shows how to use it in cancer metabolism research while separating validated product evidence from hypothesis-generating studies of the NAT1–ENO1–lactate axis.